Replies to post #128922 on Biotech Values

[north40000]

GSK/Agenus malaria vaccine is news as well

Also Gates funded, announced 2 days ago:

http://www.businessweek.com/news/2011-10-18/glaxo-vaccine-reduces-malaria-in-african-children-by-half.html

http://www.forbes.com/sites/matthewherper/2011/10/18/glaxosmithkline-bill-gates-backed-vaccine-cuts-malaria-infections-by-half/

http://www.reuters.com/article/2011/10/18/us-malaria-vaccine-gsk-idUSTRE79H58T20111018

......shares in GSK's small U.S. biotech partner Agenus, which makes a component of the vaccine, rose more than 40 percent after news of the clinical trial result.....

It seems there are a number of players in this field.

[md1225]

IBIO is in the business of lic their platform they will go as far as phase 1 with their products, then lic off to be produced on the IBIO launch. Take 1hr and go over their web site. Again I predict market cap 300 million soon. The company gets insulted when you refer them to PLX. IBIO feals they are far ahead of them with what they have, but "wall street" sees plant as plants, its not that simple.